Lareb notes newly reported deaths shortly after vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a total of 15 reports so far regarding deaths shortly after receiving the COVID-19 vaccinations.
New research in GGD test lanes on spread of coronavirus SARS-CoV-2 RIVM is launching a survey-based study this week on risk factors for the coronavirus SARS-CoV-2. The participants in this study are people who get tested for COVID-19 in a GGD test lane.
80 to 84-year-olds invited for vaccination sooner Starting tomorrow, the first people in the age group from 80-84 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
New variants disrupt plans In the past week, from 27 January to 2 February, 28,628 people in the Netherlands reportedly tested positive for COVID-19, a 20% decrease compared to the week of 20 to 26 January.
One person died shortly after COVID-19 vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a report of death shortly after receiving the Pfizer/BioNTech COVID-19 vaccination in the Netherlands.
Nationwide assessment of SARS-CoV-2 laboratories: very high quality The vast majority of the laboratories analysing COVID-19 tests are performing at the very highest standard of quality.
Building blocks for a definition of microplastics The Dutch National Institute for Public Health and the Environment, RIVM has described building blocks for a definition of microplastics.
Jacco Wallinga appointed extraordinary Professor at LUMC From 1 September, Jacco Wallinga will hold the chair in Mathematical Modelling of Infectious Diseases at the department of Medical Statistics and Bio-informatics of the Leiden University Medical Ce
Little incentive from pharmaceutical legislation to promote alternatives to animal testing Current pharmaceutical legislation does not impose any legal constraints on the use of alternatives to animal testing, but neither does it actively encourage the use of these alternatives.